Subscribe To
VALN / Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
VALN News
By GlobeNewsWire
October 11, 2023
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will pre more_horizontal
By GlobeNewsWire
August 31, 2023
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023
Saint- Herb lain (France ) , August 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that more_horizontal
By Zacks Investment Research
June 21, 2023
Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?
Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal
By GlobeNewsWire
May 31, 2023
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
Saint- Herb lain (France) , May 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its more_horizontal
By Zacks Investment Research
May 30, 2023
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program. more_horizontal
By Seeking Alpha
May 6, 2023
Valneva SE (VALN) Q1 2023 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - Chair more_horizontal
By GlobeNewsWire
March 30, 2023
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
Saint Herblain (France), March 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will prese more_horizontal
By Seeking Alpha
March 29, 2023
Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future
Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine c more_horizontal